Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: stem + cell + 0.61  Related to the article below (Last Update: 8/5/2008)

Label-Free, High-Throughput Measurements of Dynamic Changes in ...
RedOrbit, TX - Jul 29, 2008
Synthetic nanostructures inducing differentiation of human mesenchymal stem cells into neuronal lineage. Exp. Cell Res. 313:1820-1829. 21. ...
NuVasive Reports Second Quarter 2008 Financial Results
Earthtimes (press release), UK - Jul 24, 2008
The Osteocel business includes a proprietary adult stem cell bone graft product which is the only viable bone matrix product on the market that provides the ...NUVA
Source: Google News

Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation -
AV Molofsky, R Pardal, T Iwashita, IK Park, MF … - Nature, 2003 - nature.com
... in the frequency of apoptotic cells (0.59 0.61% versus 0.35 0.48 ... P0 pups, from which
SVZ CNS stem cells (g) and gut ... For both types of cell, p16 Ink4a deficiency ...

… Progression from Adult Bone Marrow to Mononucleate Muscle Stem Cell to Multinucleate Muscle Fiber … -
MA LaBarge, HM Blau - Cell, 2002 - Elsevier
... cells in the tissue-specific stem cell niche ... control group may represent a trend
(0.61 ? 0.09 relative ... contribute to differences in satellite cell number (1750 ...

[PDF] … of cytomegalovirus (CMV)?specific CD8 Tlymphocytes inT-cell?depleted stem cell grafts and after … -
JW Gratama, JWJ van Esser, CHJ Lamers, C Tournay, … - BLOOD, 2001 - publishing.eur.nl
... with the number of preemptive GCV treatment courses administered (r 0.61; P .01 ... or
not quantification of CMV-specific CD8 T cells in stem cell grafts and ...
-

In Vitro Hepatic Differentiation of Human Mesenchymal Stem Cells -
JR Chen, YP Chen, OKS Lee - Hepatology, 2004 - doi.wiley.com
... and 10 ng/mL bFGF, nicotinamide 0.61 g/L ... Differentiation of Bone Marrow? Derived
Mesenchymal Stem Cells In the absence of serum cell proliferation arrested ...

Influence of mobilized stem cells on myocardial infarct repair in a nonhuman primate model -
F Norol, P Merlet, R Isnard, P Sebillon, N Bonnet, … - Blood, 2003 - bloodjournal.hematologylibrary.org
... Stem cell mobilization. ... CD34 + cell samples and in one G-CSF + SCF CD34 - cell sample,
at a ... 4 hours after coronary ligation (from 0.43 ? 0.23 to 0.61 ? 0.26 mL ...

Mechanism of Divergent Growth Factor Effects in Mesenchymal Stem Cell Differentiation -
I Kratchmarova, B Blagoev, M Haack-Sorensen, M … - Science, 2005 - sciencemag.org
... PTK9-like protein, 0.61, 0.59. ... Such approaches could be beneficial for applications
of stem cells to direct stem cell differentiation to clinical need more ...

[PDF] … assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell … -
H Hebart, S Daginik, S Stevanovic, U Grigoleit, A … - Blood, 2002 - medizin.uni-tuebingen.de
... r 2 0.89,P < .0001andr 2 0.61,P .0045 ... specific CD4 and CD8 T-cell reconstitution
can ... infections in patients undergoing allogeneic stem cell transplantation (SCT ...
-

Neurons Generated from Adult Rat Hippocampal Stem Cells Form Functional Glutamatergic and GABAergic … -
H Toda, J Takahashi, A Mizoguchi, K Koyano, N … - Experimental Neurology, 2000 - Elsevier
... Mean amplitude of Na currents (nA) nd 0.50 0.61 0.50 0.74 0.51 ... Some soluble factors
from glia or cell/cell contact between stem cells and glia could be ...

Hirschsprung Disease Is Linked to Defects in Neural Crest Stem Cell Function -
T Iwashita, GM Kruger, R Pardal, MJ Kiel, SJ … - Science, 2003 - sciencemag.org
... Dlx5, 992, 784, 0.79, 0.56, ND. Hmgb2, 10604, 6438, 0.61, 0.70, ND. ... S3), suggesting
that there was no intrinsic defect in their stem cell potential. ...

Optimizing the CD34+ and CD34+ Thy-1+ stem cell content of peripheral blood collections. -
AK Stewart, K Imrie, A Keating, S Anania, R Nayar, … - Exp Hematol, 1995 - ncbi.nlm.nih.gov
... was noted between these candidate stem cells and the ... the peripheral WBC count (r =
0.61, p < 0.0001 ... The apheresis CD34+ cell count correlated with apheresis CFU ...

Source: Google Scholar

Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma

ATLANTA - Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

The two patients who had relapsed after the treatment regained a complete response after additional therapy.

"Our results show that this approach may actually be curative of follicular lymphoma," says lead author Issa Khouri, M.D., professor in M. D. Anderson's Department of Stem Cell Transplantation. "No other treatments produce this type of response."

The traditional treatment before receiving a matched stem cell donation consists of higher-dose chemotherapy that kills the lymphoma cells and shuts down the patient's own blood-producing stem cells - a process called myeloablation. While waiting for the donor's stem cells to engraft in the bone marrow and to begin producing blood, patients are vulnerable to infection, bleeding, and anemia.

Early research by Khouri and colleagues indicated that using a nonmyeloablative chemotherapy approach could control the lymphoma while sparing patients the side effects of high-dose chemotherapy. The transplanted blood stem cells launch an immune system attack on the lymphoma, a process called graft-vs.-lymphoma immunity.

"Our early results were encouraging. But with follicular lymphoma you need a long follow-up to see if the results hold," Khouri says. "This disease tends to recur later on, sometimes years after chemotherapy."

All patients in the present trial have been followed for at least five years, some for up to nine years. Trial patients had received 2 to 7 different chemotherapy regimens. Eight had received transplants of their own stem cells. At transplantation, 29 were in partial remission and 18 were in complete remission.

All 47 achieved complete remission after receiving matched blood stem cells from donors. One patient relapsed at 18 months. After receiving a donor lymphocyte infusion, the patient began a continuous complete response at 24 months. The other patient relapsed at 20 months and was found to have graft failure. Since treatment with rituximab, this patient has been in complete remission for four years.

Seven patients died during the trial, none from follicular lymphoma, Khouri notes. The 40 remaining patients all remain in remission. Overall survival at six years is 85 percent and current progression-free survival is 83 percent.

Acute graft-vs.-host disease (GVHD) arose in 11 percent of patients. Another 51 percent had chronic graft-vs.-host disease. GVHD was treated with immunosuppressive therapy. Khouri notes that only five patients in the study group remain on immunosuppressive therapy.

Long-term follow-up also allowed researchers to thoroughly gauge side effects, or toxicity, of the non-myeloablative approach. "It reduces toxicity significantly," Khouri says. "Even elderly patients can have this done."

Patients received fludarabine, cyclophosphamide and rituximab for three days before transplantation. Tacrolimus and methotrexate were used to prevent graft-vs.-host disease.

Follicular lymphoma is a Non-Hodgkin lymphoma, with about 12,000 new cases diagnosed annually.

###

Co-authors with Khouri are Rima M. Saliba, Martin Korbling, Chitra Hosing, Luis Fayad, Ming S. Lee, Felipe Samaniego, Barry I. Samuels, Daniel Couriel, Fredrick Hagemeister, Peter McLaughlin and Richard Champlin, all of M. D. Anderson.
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.